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We examined the use of antibiotics among 2728 women with a first diagnosis of breast cancer during 1994–2003, and 27280
population controls in North Jutland County, Denmark, based on hospital discharge diagnoses, prescription use from 1989 to 2002,
and population registry data. We found no increased relative risk of breast cancer associated with use compared with nonuse. The
odds ratio for breast cancer associated with more than 10 prescriptions for antibiotics was 1.00 (95% CI 0.86 –1.15). Relative risks
were similar for different classes of antibiotics. A subanalysis based on cases and controls younger than 70 years of age, with data on
first birth and number of children, showed similar risk estimates even after adjustment for age at first birth and parity. In our study, use
of antibiotics was not associated with an increased risk of breast cancer.
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Breast cancer is the most commonly occurring cancer in women,
but we have only limited knowledge about nonhormonal risk
factors for this malignancy (Hankinson and Hunter, 2002). Recent
case–control (Velicer et al, 2004) and cohort (Knekt et al, 2000)
studies have suggested that use of antibiotics may increase the risk
of breast cancer (Knekt et al, 2000; Velicer et al, 2004). A
mechanism for any causal association is unknown, but it has been
hypothesised that antibiotics may affect the ability of intestinal
microflora to metabolise phytochemicals from edible plants into
compounds that may protect against cancer (Setchell et al, 1981;
Velicer et al, 2003). Since antibiotics are commonly used and
breast cancer is common, any increased risk has major public
health potential.
To further evaluate this association, we conducted a population-
based case–control study of breast cancer in Denmark, a country
with one of the highest incidences of breast cancer worldwide
(National Board of Health, 2003).
METHODS
The National Health Service in each Danish county provides health
care for all residents, with free access to general practitioners and
hospitals, and also refunding a variable proportion of the costs of
prescribed drugs. All services are registered by use of the unique
10-digit civil registry number that is assigned to all Danish citizens
shortly after birth. Its use allows valid linkage between population-
based registries and the creation of a complete hospital discharge
and prescription history for each individual.
Cases with breast cancer
The Hospital Discharge Registry of North Jutland County retains
key information on all patients discharged from nonpsychiatric
hospitals in the county since 1977 (Andersen et al, 1999; Dalton
et al, 2003; Floyd et al, 2003). Registry files include information on
the civil registry number of the patient, dates of admission and
discharge, and up to 20 discharge diagnoses (Andersen et al, 1999).
Diagnoses are assigned exclusively by the doctor of record
according to the Danish version of the International Classification
of Diseases, 8th revision, and the 10th revision thereafter
(Andersen et al, 1999).
All patients with an incident diagnosis of breast cancer (ICD8:
174.00, 174.01, 174.02, 174.08, 174.09 and ICD10: C50.0–C50.6,
C50.8, C50.9) were identified in the period 1 January, 1994–31
March, 2003 (n¼2728) using the Hospital Discharge Registry.
Selection of controls
Controls were identified in the Civil Registration System, which
has had electronic records on all changes in vital status, including
change of address, date of emigration, and date of death for the
entire Danish population since 1968 and 10 controls were
randomly selected for each case, matched by year of birth and
county of residence. A total of 10 controls were selected using
incidence density sampling, that is, the controls were residents in
North Jutland County, alive and at risk for a first hospital
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diagnosed, but could be subsequently diagnosed as a case. A total
of 27280 controls were included in the study.
Data sources
The population-based Pharmaco-Epidemiological Prescription
Database of North Jutland, established in 1989, was used to
identify all prescriptions filled for antibiotics between 1989 and
2002 (Dalton et al, 2003; Floyd et al, 2003; Sørensen et al, 2004).
The county is served by pharmacies equipped with computerised
accounting systems through which data are sent to the Danish
National Health Service and to the Prescription Database, with key
information about prescriptions for refundable drugs. Thus, the
database includes information on each patient’s civil registry
number, the type of drug prescribed according to the Anatomical
Therapeutical Chemical classification system (ATC), and the date
the prescription was filled. We identified all prescriptions for
antibiotics (ATC codes: Penicillins: J01C, Cephalosporins: J01D
A01, J01D A03, J01D A06, J01D A10, J01D A11, J01D A13, J01D
A24, Macrolides: J01F, Tetracyclines: J01A, Quinolones: J01M;
Sulphonamides: J01E B02, J01E E01) among cases and controls
redeemed before the date of hospitalisation of cases. These drugs
are available in Denmark only by prescription. Before 1996,
prescriptions to children were marked with a special code and
issued to the parents, but afterwards were issued in the child’s civil
registry number; all prescriptions to children were excluded from
the analysis. Reimbursement for tetracyclines was withdrawn in
1997. Prescriptions for postmenopausal hormone replacement
therapy were also identified in the database (ATC codes:
G03C, G03D, G03F, G03H B01) and categorised as 0, 1–5,
6þprescriptions. Age at first birth and number of children were
available only for women below 70 years, ascertained through
linkage to the Danish Civil Registration System.
Statistical methods
We used conditional logistic regression to estimate odds ratios
(OR)s and associated 95% confidence intervals (CIs) for breast
cancer according to the number of prescriptions of antibiotics and
different types of antibiotics, adjusted for postmenopausal
hormone replacement therapy in the overall analysis. We adjusted
for age at first birth, parity, and use of postmenopausal hormone
replacement therapy in cases (n¼1917) and controls (n¼19170)
less than 70 years of age. Wald tests were used to test for
homogeneity.
RESULTS
Table 1 provides summary data for the 2728 cases and 27280
controls. The mean age was 62 years for both cases and controls.
Table 1 gives the ORs for breast cancer according to number of
antibiotic prescriptions. Almost all risk estimates were close to 1.0.
The ORs for breast cancer associated with more than 10
prescriptions for antibiotics was 1.00 (95% CI 0.86–1.15). There
were no substantial differences in findings for various classes of
antibiotics (penicillins, cephalosporins, macrolides, tetracyclines,
quinolones, and sulphonamides) (Table 2). In women less than 70
years of age, the adjusted OR for breast cancer was 1.11 (95% CI
0.93–1.32) for women with more than 10 prescriptions.
Relative risks did not vary substantially between parous and
nulliparous women (data not shown).
DISCUSSION
In this large population-based case–control study, we found no
increased risk of breast cancer in association with antibiotic use.
Table 1 Risk of breast cancer according to number of prescriptions for
antibiotics
Cases Controls
No. of prescriptions No. % No. % OR 95% CI
0 489 17.9 5047 18.5 1 (reference) —
1–5 1327 48.6 13078 47.9 1.02 0.91–1.14
6–10 467 17.1 4859 17.8 0.94 0.82–1.08
410 445 16.3 4296 15.7 1.00 0.86–1.15
Wald test for homogeneity P¼0.35
Table 2 Risk of breast cancer according to types of antibiotics
Cases Controls
Type of antibiotic No. % No. % OR 95% CI
Penicillins Overall 1974 72.4 19589 71.8 1.00 0.91–1.10
More than 10 prescriptions 204 7.5 2087 7.7 0.94 0.80–1.12
Cephalosporins
a Overall 1 0.0 24 0.1 0.41 0.06–3.01
More than 10 prescriptions 0 — 6 0.0 — —
Macrolides Overall 891 32.7 8381 30.7 1.07 0.98–1.17
More than 10 prescriptions 22 0.8 260 1.0 0.85 0.55–1.31
Tetracyclines Overall 344 12.6 3202 11.7 1.05 0.93–1.19
More than 10 prescriptions 11 0.4 73 0.3 1.44 0.76–2.73
Quinolones Overall 195 7.2 1828 6.7 1.02 0.88–1.19
More than 10 prescriptions 4 0.1 35 0.1 1.05 0.37–2.95
Sulphonamides Overall 818 30.0 8468 31.0 0.92 0.84–1.00
More than 10 prescriptions 22 0.8 285 1.0 0.68 0.44–1.06
aIn Denmark, cephalosporins are almost solely used in hospitals.
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control study of 2266 women with breast cancer and 7953 controls
(Velicer et al, 2004). In that investigation, the relative risk was
1.56–2.66 for more than 10 prescriptions, but the effect was also
seen in the category of 1–10 prescriptions with an OR of 1.49 (95%
CI 1.28 –1.79) (Velicer et al, 2004). In a subanalysis, an increased
risk of fatal breast cancer was seen for all antibiotic classes (Velicer
et al, 2004). In a Finnish cohort study of women younger than 50
years of age, self-reported antibiotic use for urinary tract infections
was associated with a breast cancer relative risk of 1.74 (95% CI
1.13 –2.68) (Knekt et al, 2000).
Several issues are relevant to the interpretation of our data. The
main strengths of this study are its large size, the population-based
design based on the Danish health-care system, and the use of
exposure data collected before hospitalisation for breast cancer.
These data sources have been extensively used in previous
pharmacoepidemiological studies (Pedersen et al, 1999; Sørensen
et al, 2000; Nielsen et al, 2001; Dalton et al, 2003; Floyd et al, 2003;
Sørensen et al, 2004). A limitation is the shorter latency period of
maximum 15 years relative to the Seattle study in which the
maximum period of exposure to antibiotics was 25 years (Velicer
et al, 2004). Also, we had no information for certain breast cancer
risk factors such as alcohol consumption. However, confounding
factors would have to be related to antibiotic prescriptions and
inversely related to breast cancer risk, conditionally adjusted for
age, which is an unlikely combination. No restrictions were
imposed concerning the length of time cases or controls should
have lived in North Jutland County. We obtained prescription data
on cases for a mean number of days of 3478 (median: 3508) and,
for controls, 3468 (median: 3502), or approximately 9.5 years.
In conclusion, the present data showed no increased breast
cancer risk among antibiotic users in a population characterised by
one of the highest breast cancer incidence rates worldwide (National
Board of Health, 2003), although further study would be useful.
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